MolMet Supp 4: GK enhances nuclear sequestration of GKRP(446P and 446L) in FTO2B (A-E) and HeLa (F-H) cells.
A) GK and hexokinase I immunoactivity in FTO2B cells, untreated or treated with a GK adenoviral vector.
B) GKRP immunoactivity in FTO2B cells transfected for expression of human or mouse GKRP (hp, hL, mP, mL at 25 x 106 pfu/ml) and -/+ expression of GK.
C) GKRP and GK immunostaining in FTO2B cells
D) Nuclear sequestration of GKRP (N/C intensity ratio) is increased by GK expression (* P < 0.001). Means ± SEM for the fields indicated in 4 experiments.
E) GK N/C intensity ratios in GK transfections. $ P<0.05 mP vs hP.
F-G). GKRP immunoactivity (F) and immunostaining (G) in HeLa cells transfected for expression of human or mouse GKRP (hP, hL, mP, mL) at titres of 10-25 x 106 pfu/ml -/+ expression of GK.
H) Nuclear sequestration of GKRP (N/C intensity ratio) is increased by GK expression (*P < 0.001) and is lower with GKRP-446L (# P<0.03) in the presence of GK expression. Means ± SEM for the fields indicated in 2 experiments.
Funding
MICA: Exploring a new perspective on the mechanism of action of Glucokinase Activators in liver, a preclinical study
Medical Research Council
Find out more...
